B2B Strategic Consulting

Our Vision of Autoimmune Care

Autoimmune Patient Journey The convoluted journey of patients with autoimmune and inflammatory diseases (AIIDs) has many stages. Unlike cancer, diabetes, and heart disease, there are no population screening nor public health education programs for AIIDs. This blocks the path to early diagnosis and preventative autoimmune care.  As early symptoms fluctuate

Read More »

The NIH Report: “Enhancing NIH Research on Autoimmune Disease”

May 2022 Report This May 2022 549-page NIH report represents a significant breakthrough in autoimmune research focus. Its recommendations have major downstream implications for CDC statistics, basic research, R&D, medical education & clinical guidelines. Funded and launched in 2019, before the pandemic but even more relevant since COVID-19 spotlighted post-viral

Read More »

Autoimmune Incidence & Prevalence

Data Issues in Autoimmune Data for autoimmune diseases are substantially lacking and inconsistent. The US gathers no statistics on autoimmune diseases as a group, nor even national data on marquee diseases. Therefore, total autoimmune incidence & prevalence figures are, at best, estimates. Unlike cancer, there is no national strategic research

Read More »

Siloed Specialties & Treatments for Autoimmune Diseases

Autoimmune Diseases are Siloed by Specialty Click the arrows next to the slide to view the sources. Looks a mess, doesn’t it? It is! Autoimmune diseases are scattered across many different medical specialties, creating a siloed landscape in which patients must coordinate and navigate for themselves. This illustration maps high-prevalence

Read More »

The Chronic Disease Epidemic: Visible & Invisible

The Visible Chronic Disease Epidemic Click the arrows next to the slide to view the sources. The chronic disease population has grown substantially in recent years since modern medicine has extended the human lifespan. Depending on sources, 40-60% of Americans (128-140M people) have one or more chronic health conditions. Moreover,

Read More »

A Patient Journey Solution (Part 3): Digitally Enabled V1C
A solution to convoluted autoimmune patient journeys?

Digitally enabled, virtual first care (V1C) offers a potential solution to convoluted autoimmune patient journeys. V1C especially offers significant advantages for autoimmune and inflammatory disease (AIID) patients in accessing specialized care. Virtual specialist practices get patients to a rheumatologist or gastroenterologist much faster (days rather than months) and with less

Read More »

Long and Frustrating Autoimmune Patient Journeys (Part 1)

Slow & Uncoordinated Path to Diagnosis & Treatment Today, autoimmune patient journeys are typically long, convoluted, and frustrating; from first awareness of symptoms to scheduling medical visits, diagnosis, treatment, and long-term care. Since many autoimmune & inflammatory diseases (AIIDs) emerge in youth or middle age and last a lifetime, the

Read More »

Specialty Pharmaceuticals: The Highest Autoimmune Cost

Invisible Epidemic of Autoimmune Disease As we continue to illuminate the hidden costs of the long-ignored epidemic of autoimmune disease (AIID), we must shine a light on the highest autoimmune cost: Specialty pharmaceuticals. Current data largely underestimate total AIID costs, and accurate numbers are few and far between. Through our

Read More »

The Total Cost Burden of the Autoimmune Epidemic

The Problem: We Don’t Really Know! The problem with estimating the total cost burden of the autoimmune disease (AIID) epidemic is that we really don’t know! A May 2022 NIH report validates our long-held belief that missing and inconsistent data for autoimmune diseases (AIIDs) are at the root of the

Read More »